Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisGordon R. Bernard, Charles J. Fisher, Jean‐Louis Vincent et al.|New England Journal of Medicine|2001Cited by 6.1k
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisE. Wesley Ely, Gordon R. Bernard, Pierre‐François Laterre et al.|Critical Care Medicine|2003Cited by 283
The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)GR Bernard, Jean‐Louis Vincent, JS Steingrub et al.|Digital Access to Libraries|2001Cited by 213
Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomalleiSteven P. LaRosa, Charles J. Fisher, Wipada Chaowagul et al.|International Journal of Infectious Diseases|2005Cited by 45